The Case for Prompt Salvage Infant Peanut Oral Immunotherapy Following Failed Primary Prevention

J Allergy Clin Immunol Pract. 2022 Oct;10(10):2561-2569. doi: 10.1016/j.jaip.2022.05.040. Epub 2022 Jun 23.

Abstract

Recent guideline recommendations have shifted from recommending prolonged avoidance of allergenic foods in the first 3 years of life to a primary prevention approach involving the deliberate early introduction to infants at risk of developing food allergy. Despite this, some infants, especially those with severe eczema who are at highest risk for developing peanut allergy, fail to receive the preventative benefits of early peanut introduction due to hesitancy and other factors. Difficulty adhering to regular ingestion after introduction further reduces the effectiveness of primary prevention. As emerging real-world evidence has demonstrated that performing peanut oral immunotherapy (OIT) among infants is effective and safe, peanut OIT could be a treatment option for infants with peanut allergy. This review discusses the benefits, risks, and barriers to offering peanut OIT to infants who fail primary prevention strategies. We propose the novel concept that infants with peanut allergy be offered peanut OIT as soon as possible after failed peanut introduction through a shared decision-making process with the family, where there is a preference for active management rather than avoidance.

Keywords: Barriers; Infants; Oral immunotherapy; Peanut allergy; Prevention.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Allergens / therapeutic use
  • Arachis
  • Desensitization, Immunologic
  • Food Hypersensitivity* / prevention & control
  • Humans
  • Immunologic Factors
  • Infant
  • Peanut Hypersensitivity* / prevention & control
  • Primary Prevention

Substances

  • Allergens
  • Immunologic Factors